Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
C Venkata S RamTexas Blood Pressure Institute, Clinical Research Institute of Dallas Nephrology Associates; and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USAAbstract: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin recept...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-05-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/reappraisal-of-role-of-angiotensin-receptor-blockers-in-cardiovascular-peer-reviewed-article-VHRM |
| _version_ | 1819293123520495616 |
|---|---|
| author | Ram CV |
| author_facet | Ram CV |
| author_sort | Ram CV |
| collection | DOAJ |
| description | C Venkata S RamTexas Blood Pressure Institute, Clinical Research Institute of Dallas Nephrology Associates; and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USAAbstract: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability profile with similar renoprotective properties compared with ramipril, suggesting a potential clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in cardioprotection and renoprotection for high-risk patients.Keywords: angiotensin receptor blockers, hypertension, outcomes, clinical trials |
| first_indexed | 2024-12-24T04:05:25Z |
| format | Article |
| id | doaj.art-1131c0a5beb14a9a97131ade3656f5ef |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-24T04:05:25Z |
| publishDate | 2011-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-1131c0a5beb14a9a97131ade3656f5ef2022-12-21T17:16:12ZengDove Medical PressVascular Health and Risk Management1178-20482011-05-01Volume 73153197462Reappraisal of role of angiotensin receptor blockers in cardiovascular protectionRam CVC Venkata S RamTexas Blood Pressure Institute, Clinical Research Institute of Dallas Nephrology Associates; and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USAAbstract: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability profile with similar renoprotective properties compared with ramipril, suggesting a potential clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in cardioprotection and renoprotection for high-risk patients.Keywords: angiotensin receptor blockers, hypertension, outcomes, clinical trialshttps://www.dovepress.com/reappraisal-of-role-of-angiotensin-receptor-blockers-in-cardiovascular-peer-reviewed-article-VHRMAngiotensin receptor blockershypertensionoutcomesclinical trials |
| spellingShingle | Ram CV Reappraisal of role of angiotensin receptor blockers in cardiovascular protection Vascular Health and Risk Management Angiotensin receptor blockers hypertension outcomes clinical trials |
| title | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| title_full | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| title_fullStr | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| title_full_unstemmed | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| title_short | Reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| title_sort | reappraisal of role of angiotensin receptor blockers in cardiovascular protection |
| topic | Angiotensin receptor blockers hypertension outcomes clinical trials |
| url | https://www.dovepress.com/reappraisal-of-role-of-angiotensin-receptor-blockers-in-cardiovascular-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT ramcv reappraisalofroleofangiotensinreceptorblockersincardiovascularprotection |